Small RNA-based therapy for pulmonary arterial hypertension: MiRNA-491-5p inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 7/August/2016, 2.58 pm

Small ribonucleic acid medicine therapy for Myocardial Infarction: MiRNA-520/373 improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 7/August/2016, 1.41 pm
August 7, 2016
MiRNA therapy for Intestinal cancer: MiRNA-1976 increases the expression of DNA Sensor AIM2 and inhibits expansion of tumor-initiating intestinal stem cell population via up regulation of its target gene, 7/August/2016, 3.24 pm
August 7, 2016
Show all

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November  2009 issue of the journalNature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054] by Prof. Thistlethwaite PA, Li X and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small RNA-based therapy for pulmonary arterial hypertension: MiRNA-491-5p inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3

Significance:  

Given that: (1) one billion people have hypertension every year worldwide; (2) 0.66 billion people have hypertension from developing countries every year worldwide; (4) hypertension is one of the top 10 causes of death worldwide; and (4) 9.4 million people worldwide die of complications of hypertension every year worldwide, there is an urgent need to find: (i) a side-effect-free drug; and (ii) a way to effectively treat and cure high blood pressure. 

This study suggests, for the first time, that MiRNA-491-5p, by decreasing the expression of its target gene Notch3, it may lower blood pressure. Thus, pharmacological formulations encompassing MiRNA-491-5p activators” may be used to treat pulmonary arterial hypertension

Undisclosed information: How MiRNA-491-5p inhibits the development of pulmonary arterial hypertension

Amount: $100

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

To citeBoominathan, Small RNA-based therapy for pulmonary arterial hypertension: MiRNA-491-5p inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 7/August/2016,  2.58 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.